SG177959A1 - Methods for increasing and mobilizing hematopoietic stem cells - Google Patents

Methods for increasing and mobilizing hematopoietic stem cells Download PDF

Info

Publication number
SG177959A1
SG177959A1 SG2012001392A SG2012001392A SG177959A1 SG 177959 A1 SG177959 A1 SG 177959A1 SG 2012001392 A SG2012001392 A SG 2012001392A SG 2012001392 A SG2012001392 A SG 2012001392A SG 177959 A1 SG177959 A1 SG 177959A1
Authority
SG
Singapore
Prior art keywords
cells
hsc
blood
cell
amd3100
Prior art date
Application number
SG2012001392A
Other languages
English (en)
Inventor
Alexander Shakhov
Evguenia Strom
Original Assignee
Cleveland Biolabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Biolabs Inc filed Critical Cleveland Biolabs Inc
Publication of SG177959A1 publication Critical patent/SG177959A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG2012001392A 2007-01-09 2008-01-09 Methods for increasing and mobilizing hematopoietic stem cells SG177959A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88416207P 2007-01-09 2007-01-09
US88989307P 2007-02-14 2007-02-14
US93856407P 2007-05-17 2007-05-17
US1324307P 2007-12-12 2007-12-12

Publications (1)

Publication Number Publication Date
SG177959A1 true SG177959A1 (en) 2012-02-28

Family

ID=39609361

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012001392A SG177959A1 (en) 2007-01-09 2008-01-09 Methods for increasing and mobilizing hematopoietic stem cells

Country Status (14)

Country Link
US (3) US20100055077A1 (enExample)
EP (1) EP2115124B1 (enExample)
JP (1) JP5389666B2 (enExample)
KR (1) KR101493474B1 (enExample)
CN (1) CN101631850B (enExample)
BR (1) BRPI0806557A2 (enExample)
CA (1) CA2675032A1 (enExample)
EA (1) EA018983B1 (enExample)
IL (1) IL199766A (enExample)
MX (1) MX2009007391A (enExample)
NZ (2) NZ578928A (enExample)
SG (1) SG177959A1 (enExample)
WO (1) WO2008086426A2 (enExample)
ZA (1) ZA200905378B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2612102C (en) 2005-06-13 2016-02-09 Cleveland Biolabs, Inc. Methods of protecting against apoptosis using lipopeptides
DK2032701T3 (da) * 2006-06-23 2014-02-10 Alethia Biotherapeutics Inc Polynukleotider og polypeptider, der er inddraget i cancer
JP5781932B2 (ja) 2008-11-03 2015-09-24 アレシア・バイオセラピューティクス・インコーポレーテッド 腫瘍抗原の生物活性を特異的にブロックする抗体
US20130039882A1 (en) * 2009-10-28 2013-02-14 Henry Ford Health System Method to mitigate injury from radiation exposure
EP2338521A1 (en) * 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
US20130230580A1 (en) * 2010-09-14 2013-09-05 Paul S. Frenette Administration of SNS Neuroprotective Agents to Promote Hematopoietic Regeneration
EP2691421B1 (en) 2011-03-31 2016-11-09 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
EA201992513A1 (ru) 2012-01-09 2020-05-31 Адс Терапьютикс Са Способ лечения рака груди
WO2013149064A1 (en) * 2012-03-30 2013-10-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells
EP2838614B1 (en) 2012-04-20 2019-09-11 GB006, Inc. Compositions for regulating integrins
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
JP2016518415A (ja) * 2013-10-21 2016-06-23 アドバンスド ニューロリジェネレイティブ セラピーズ エルエルシー 加齢と疾患免疫機能障害と細胞老化とをリンパ球系幹細胞で修復する方法、及び治療使用のためのそれらの再適用する方法
CN104744563B (zh) * 2013-12-27 2019-02-26 中国人民解放军军事医学科学院毒物药物研究所 端基具有亲脂性结构的线性脂肽、其制备方法及用途
WO2016073733A1 (en) * 2014-11-06 2016-05-12 Cleveland Biolabs, Inc. Methods of treating cancer using lipopeptides
US20210189344A1 (en) * 2018-08-30 2021-06-24 The Regents Of The University Of California Mobilization and collection of peripheral blood hematopoietic stem cells from deceased donors
CN112851755B (zh) * 2021-01-13 2023-09-01 中国人民解放军军事科学院军事医学研究院 一种线性脂肽化合物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
DE19822820A1 (de) * 1998-05-20 1999-11-25 Biotechnolog Forschung Gmbh Pharmazeutisches Präparat zur Wundbehandlung
CA2612102C (en) * 2005-06-13 2016-02-09 Cleveland Biolabs, Inc. Methods of protecting against apoptosis using lipopeptides
CA2659337A1 (en) * 2006-08-07 2008-02-14 Genzyme Corporation Combination therapy

Also Published As

Publication number Publication date
NZ578928A (en) 2013-03-28
AU2008204836A1 (en) 2008-07-17
WO2008086426A8 (en) 2009-07-30
KR101493474B1 (ko) 2015-02-16
EA018983B1 (ru) 2013-12-30
US20100055077A1 (en) 2010-03-04
BRPI0806557A2 (pt) 2014-04-15
US20140045747A1 (en) 2014-02-13
IL199766A (en) 2015-01-29
EA200900806A1 (ru) 2010-08-30
EP2115124A2 (en) 2009-11-11
WO2008086426A2 (en) 2008-07-17
ZA200905378B (en) 2010-05-26
WO2008086426A3 (en) 2008-12-18
CA2675032A1 (en) 2008-07-17
JP5389666B2 (ja) 2014-01-15
KR20090108703A (ko) 2009-10-16
MX2009007391A (es) 2009-08-13
NZ603805A (en) 2014-03-28
JP2010515748A (ja) 2010-05-13
US20150174195A1 (en) 2015-06-25
HK1134835A1 (en) 2010-05-14
EP2115124A4 (en) 2012-05-30
EP2115124B1 (en) 2016-03-16
CN101631850A (zh) 2010-01-20
CN101631850B (zh) 2013-12-04

Similar Documents

Publication Publication Date Title
SG177959A1 (en) Methods for increasing and mobilizing hematopoietic stem cells
ES2538305T3 (es) Métodos para expandir poblaciones de células mieloides y usos de las mismas
US6784155B1 (en) Inhibitor and stimulator of stem cell proliferation and uses thereof
RU2747728C2 (ru) Применение размноженных популяций гематопоэтических стволовых клеток/клеток-предшественников
US20250032549A1 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
KR20050093759A (ko) 혈소판 및 조혈 줄기세포의 생산을 증가시키는 방법
BR112020011186A2 (pt) regimes de dosagem para a mobilização de células-tronco e progenitoras hematopoiéticas
Basser et al. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.
AU2008204836B2 (en) Methods for increasing and mobilizing hematopoietic stem cells
WO2002033043A2 (en) Method and marker for the isolation of human multipotent hematopoietic stem cells
Tijssen et al. Clinical approaches involving thrombopoietin to shorten the period of thrombocytopenia after high-dose chemotherapy
US20230414565A1 (en) Compositions and methods for treating hematological malignancies
Araki et al. cMPL-Based Purification and Depletion of Human Hematopoietic Stem Cells: Implications for Pre-Transplant Conditioning [preprint]
HK1134835B (en) Methods for increasing and mobilizing hematopoietic stem cells
WO2022197776A1 (en) Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
WO2019099615A1 (en) Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth
NZ504512A (en) Peptide from alpha-hemoglobin as a stimulator of stem cell proliferation and used thereof
DE DK et al. NUKLEINSÄURE, WELCHE EINEN VON LEKTIN ABSTAMMENDEN FAKTOR ZUR PRÄSERVIERUNG VON PROGENITORZELLEN KODIERT ACIDE NUCLEIQUE CODANT UN FACTEUR DE CONSERVATION DE CELLULES PROGENITRICES DERIVE DE LA LECTINE
Corbí Pathogen recognition by dendritic cells: Role of C-type lectins
MXPA98008178A (es) Inhibidor y estimulador de la proliferación de células totipotentes y sus usos